Skip to Main Content

WASHINGTON — Several drug companies are considering “substantial and material decreases” in the prices for their drugs, Health and Human Services Secretary Alex Azar said at a congressional hearing Tuesday.

“There are actually several drug companies that are looking at substantial and material decreases in drug prices, in competitive classes, and actually competing with each other and looking to do that,” Azar said, declining to name the specific companies or products.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.